Top Markets
Coin of the day
Novartis AG Novartis AG

Novartis AG

NOVN
Classifica tra le azioni #57
Novartis AG researches, develops, manufactures, distributes, markets, and sells... Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still’s disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Prezzo delle azioni
$149.90
Ultima sincronizzazione: 2026-09-18
Capitalizzazione di mercato
$284.92B
Variazione (1 giorno)
-0.66%
Variazione (1 anno)
21.93%
Paese
CH
Scambia Novartis AG (NOVN)

Categoria

Storico dividendi per Novartis AG (NOVN)
Novartis AG (simbolo azionario: NOVN) ha effettuato un totale di 29 pagamenti di dividendi.
La somma totale dei dividendi (rettificata per split azionari) è: $57.55
Rendimento da dividendo (TTM): 0.028
Pagamenti dei dividendi per Novartis AG (NOVN) dal 1997 al 2026
Pagamenti annuali dei dividendi
Anno Dividendo (rettificato per split azionari) Cambia
2026 (TTM) $3.50 0.00%
2025 $3.50 6.06%
2024 $3.30 3.12%
2023 $3.20 3.23%
2022 $3.10 3.33%
2021 $3.00 1.69%
2020 $2.95 3.51%
2019 $2.85 1.79%
2018 $2.80 1.82%
2017 $2.75 1.85%
2016 $2.70 3.85%
2015 $2.60 6.12%
2014 $2.45 6.52%
2013 $2.30 2.22%
2012 $2.25 2.27%
2011 $2.20 4.76%
2010 $2.10 5.00%
2009 $2.00 25.00%
2008 $1.60 18.52%
2007 $1.35 17.39%
2006 $1.15 9.52%
2005 $1.05 5.00%
2004 $1.00 5.26%
2003 $0.95 5.56%
2002 $0.9 5.88%
2001 $0.85 6.25%
2000 $0.8 10.34%
1999 $0.725 16.00%
1998 $0.625 25.00%
1997 $0.5 0.00%
Elenco di tutti i pagamenti di dividendi
Anno Dividendo Cambia
2026 (TTM) $3.50 0.00%
2025 $3.50 6.06%
2024 $3.30 -14.06%
2023 $3.84 23.87%
2022 $3.10 3.33%
2021 $3.00 1.69%
2020 $2.95 3.51%
2019 $2.85 1.79%
2018 $2.80 1.82%
2017 $2.75 1.85%
2016 $2.70 3.85%
2015 $2.60 6.12%
2014 $2.45 6.52%
2013 $2.30 2.22%
2012 $2.25 2.27%
2011 $2.20 4.76%
2010 $2.10 5.00%
2009 $2.00 25.00%
2008 $1.60 18.52%
2007 $1.35 17.39%
2006 $1.15 9.52%
2005 $1.05 5.00%
2004 $1.00 5.26%
2003 $0.95 5.56%
2002 $0.9 -97.35%
2001 $34.00 6.25%
2000 $32.00 10.34%
1999 $29.00 16.00%
1998 $25.00 25.00%
1997 $20.00 0.00%
Dividendi di aziende simili o concorrenti
Azienda Numero di pagamenti di dividendi Il paese
215.00%
US
225.00%
US
53.00%
US
33.00%
CH
223.00%
US